文献速递产科母胎医学

抗生素治疗降低未足月胎膜早破患者羊膜腔内炎症发生率

Antibiotic administration reduces the rate of intraamniotic inflammation in preterm prelabor rupture of the membranes.
PubMed 文献 · Am J Obstet Gynecol · 2020-01-01

这项回顾性队列研究纳入270例24+0至33+6周未足月胎膜早破(PPROM)单胎孕妇,比较抗生素治疗前后羊水中白细胞介素-6浓度及解脲脲原体DNA载量。结果显示,静脉克拉霉素治疗与羊膜腔内感染及无菌性羊膜腔内炎症患者羊水白细胞介素-6浓度下降相关,并与解脲脲原体DNA载量降低相关。

要点

  • PPROM患者静脉克拉霉素治疗后羊水白细胞介素-6浓度较治疗前下降。
  • 克拉霉素治疗与羊水中解脲脲原体DNA载量较治疗前降低相关。
  • 研究为回顾性队列,随访羊膜腔穿刺仅在潜伏期超过7天的患者中进行。

核心结论

  • 静脉克拉霉素治疗与PPROM合并羊膜腔内感染或无菌性羊膜腔内炎症患者羊膜腔内炎症反应强度降低相关。
  • 克拉霉素治疗与妊娠不足34周PPROM患者羊水中解脲脲原体DNA载量降低相关。

研究设计与样本

  • 回顾性队列研究,纳入270例单胎妊娠、24+0至33+6周PPROM、入院时行经腹羊膜腔穿刺并接受静脉抗生素治疗7天的患者。
  • 有羊膜腔内炎症者使用克拉霉素,无羊膜腔内炎症且过敏者使用苄青霉素/克林霉素;潜伏期超过7天者于入院第7天行随访羊膜腔穿刺。
  • 羊水白细胞介素-6用床旁试验检测,羊膜腔内微生物入侵用培养和分子微生物学方法评估。
  • 羊膜腔内炎症定义为羊水床旁白细胞介素-6浓度≥745 pg/mL;羊膜腔内感染定义为微生物入侵加羊膜腔内炎症;无菌性羊膜腔内炎症定义为有羊膜腔内炎症但无微生物入侵。

主要发现

  • 270例中207例在7天内分娩,63例在入院7天后分娩;63例中40例接受了随访羊膜腔穿刺。
  • 羊膜腔内感染患者(n=7)克拉霉素治疗后随访羊水白细胞介素-6中位数295 pg/mL(IQR 72-673)vs 初始中位数2973 pg/mL(IQR 1750-6296),P=.02。
  • 无菌性羊膜腔内炎症患者(n=7)克拉霉素治疗后随访羊水白细胞介素-6中位数221 pg/mL(IQR 118-366)vs 初始中位数1446 pg/mL(IQR 1300-2941),P=.02。
  • 含解脲脲原体DNA的羊水样本随访时DNA载量中位数1.8×10^4 copies DNA/mL(IQR 2.9×10^4至6.7×10^8)vs 初始中位数4.7×10^7 copies DNA/mL(IQR 2.9×10^3至3.6×10^7),P=.03。
  • 无微生物入侵且无羊膜腔内炎症患者(n=26)接受苄青霉素或克林霉素治疗。

关键数值与推荐

  • 羊膜腔内炎症:羊水床旁白细胞介素-6浓度≥745 pg/mL。
  • 羊膜腔内感染:微生物入侵羊膜腔且存在羊膜腔内炎症。
  • 无菌性羊膜腔内炎症:存在羊膜腔内炎症但无微生物入侵羊膜腔。
  • 抗生素方案:有羊膜腔内炎症者静脉克拉霉素;无羊膜腔内炎症且过敏者用苄青霉素/克林霉素;疗程7天。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preterm prelabor rupture of the membranes (PPROM) is frequently complicated by intraamniotic inflammatory processes such as intraamniotic infection and sterile intraamniotic inflammation. Antibiotic therapy is recommended to patients with PPROM to prolong the interval between this complication and delivery (latency period), reduce the risk of clinical chorioamnionitis, and improve neonatal outcome. However, there is a lack of information regarding whether the administration of antibiotics can reduce the intensity of the intraamniotic inflammatory response or eradicate microorganisms in patients with PPROM. OBJECTIVE: The first aim of the study was to determine whether antimicrobial agents can reduce the magnitude of the intraamniotic inflammatory response in patients with PPROM by assessing the concentrations of interleukin-6 in amniotic fluid before and after antibiotic treatment. The second aim was to determine whether treatment with intravenous clarithromycin changes the microbial load of Ureaplasma spp DNA in amniotic fluid. STUDY DESIGN: A retrospective cohort study included patients who had (1) a singleton gestation, (2) PPROM between 24+0 and 33+6 weeks, (3) a transabdominal amniocentesis at the time of admission, and (4) intravenous antibiotic treatment (clarithromycin for patients with intraamniotic inflammation and benzylpenicillin/clindamycin in the cases of allergy in patients without intraamniotic inflammation) for 7 days. Follow-up amniocenteses (7th day after admission) were performed in the subset of patients with a latency period lasting longer than 7 days. Concentrations of interleukin-6 were measured in the samples of amniotic fluid with a bedside test, and the presence of microbial invasion of the amniotic cavity was assessed with culture and molecular microbiological methods. Intraamniotic inflammation was defined as a bedside interleukin-6 concentration ≥745 pg/mL in the samples of amniotic fluid. Intraamniotic infection was defined as the presence of both microbial invasion of the amniotic cavity and intraamniotic inflammation; sterile intraamniotic inflammation was defined as the presence of intraamniotic inflammation without microbial invasion of the amniotic cavity. RESULTS: A total of 270 patients with PPROM were included in this study: 207 patients delivered within 7 days and 63 patients delivered after 7 days of admission. Of the 63 patients who delivered after 7 days following the initial amniocentesis, 40 underwent a follow-up amniocentesis. Patients with intraamniotic infection (n = 7) and sterile intraamniotic inflammation (n = 7) were treated with intravenous clarithromycin. Patients without either microbial invasion of the amniotic cavity or intraamniotic inflammation (n = 26) were treated with benzylpenicillin or clindamycin. Treatment with clarithromycin decreased the interleukin-6 concentration in amniotic fluid at the follow-up amniocentesis compared to the initial amniocentesis in patients with intraamniotic infection (follow-up: median, 295 pg/mL, interquartile range [IQR], 72-673 vs initial: median, 2973 pg/mL, IQR, 1750-6296; P = .02) and in those with sterile intraamniotic inflammation (follow-up: median, 221 pg/mL, IQR 118-366 pg/mL vs initial: median, 1446 pg/mL, IQR, 1300-2941; P = .02). Samples of amniotic fluid with Ureaplasma spp DNA had a lower microbial load at the time of follow-up amniocentesis compared to the initial amniocentesis (follow-up: median, 1.8 × 104 copies DNA/mL, 2.9 × 104 to 6.7 × 108 vs initial: median, 4.7 × 107 copies DNA/mL, interquartile range, 2.9 × 103 to 3.6 × 107; P = .03). CONCLUSION: Intravenous therapy with clarithromycin was associated with a reduction in the intensity of the intraamniotic inflammatory response in patients with PPROM with either intraamniotic infection or sterile intraamniotic inflammation. Moreover, treatment with clarithromycin was related to a reduction in the load of Ureaplasma spp DNA in the amniotic fluid of patients with PPROM <34 weeks of gestation.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Kacerovsky M, Romero R, Stepan M, et al. Antibiotic administration reduces the rate of intraamniotic inflammation in preterm prelabor rupture of the membranes. Am J Obstet Gynecol. 2020. PMID: 32591087. doi:10.1016/j.ajog.2020.01.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。